Results 241 to 250 of about 7,978,447 (307)

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor   +11 more
wiley   +1 more source

A scoping review of adverse events associated with concomitant beta‐adrenoreceptor blockers and selective serotonin reuptake inhibitors

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Beta‐adrenoreceptor blockers (beta‐blockers) and selective serotonin reuptake inhibitors (SSRIs) are commonly used medications and often used together, such as for the treatment of anxiety. However, there is no recent review of any potential adverse events related to concomitant use of medicines from each group.
Ziyi Cai   +10 more
wiley   +1 more source

Long‐term cost‐effectiveness of belatacept vs. tacrolimus in kidney transplantation: Trade‐off between metabolic benefit and immunological risk

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the long‐term cost‐effectiveness of belatacept vs. tacrolimus as maintenance immunosuppression in adult kidney transplant recipients, focusing on the trade‐off between reduced new‐onset diabetes after transplantation (NODAT), immunological risk and potential renal benefit.
Salvatore Di Maria   +2 more
wiley   +1 more source

Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial. [PDF]

open access: yesEuropace
Lee S   +29 more
europepmc   +1 more source

Pharmacokinetic and pharmacodynamic interaction of enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, with glimepiride and metformin in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, is expected to be coadministered with antihyperglycaemic drugs with different mechanisms of action. This study aimed to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between enavogliflozin, glimepiride and metformin.
Kyungrin Chang   +5 more
wiley   +1 more source

Patient preferences for medicines information in cardiovascular disease and the influence of unmet needs on medication adherence: A cross‐sectional study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
A survey of 313 Australians with cardiovascular disease found strong preferences for digitally delivered medicine information. Half of participants reported unmet information needs related to their medicines, which were associated with lower medication adherence.
Lachlan L. Dalli   +7 more
wiley   +1 more source

Immobilization of Alginate Microbeads With Whole‐Cells Expressing Nitrilase for Continuous Nicotinic Acid Production in Chip Millireactor

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT The biocatalytic production of nicotinic acid using nitrilases has emerged as a promising alternative to conventional chemical synthesis, offering improved selectivity and environmental sustainability. In this study, we developed a continuous‐flow millireactor system employing Escherichia coli cells expressing a nitrilase from Paraburkholderia
Jonathan Bassut   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy